news
First half year 2014: Boehringer Ingelheim meets challenges
11 August 2014 | By Boehringer Ingelheim
The research-driven pharmaceutical company Boehringer Ingelheim overcame major challenges in the first half of 2014...
List view / Grid view
Boehringer Ingelheim
news
Boehringer Ingelheim receives two FDA approvals
4 August 2014 | By Boehringer Ingelheim
Boehringer Ingelheim today announced the U.S. Food and Drug Administration (FDA) approved two different products at the end of last week.
news
Boehringer Ingelheim establishes a research alliance with the University of Toronto, the Toronto-based University Health Network and the Mount Sinai Hospital
22 July 2014 | By Boehringer Ingelheim
...to investigate new therapeutic concepts in the field of ubiquitin signalling biology.
news
Boehringer Ingelheim’s investigational therapy nintedanib* receives the first FDA breakthrough therapy designation in IPF
17 July 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that for the first time the U.S. Food & Drug Administration has granted Breakthrough Therapy designation for a treatment in idiopathic pulmonary fibrosis...
news
Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients
9 July 2014 | By Boehringer Ingelheim
Results from a Phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia aged 65 or older and ineligible for intensive remission induction therapy, lived longer...
news
Judit Makara wins Boehringer Ingelheim’s FENS Award 2014 for Exceptional Research in Neuroscience
7 July 2014 | By Boehringer Ingelheim
This year's Boehringer Ingelheim FENS Award was granted to Judit Makara from the Institute of Experimental Medicine of the Hungarian Academy of Sciences in Budapest, Hungary...
news
Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat® fixed-dose combination in COPD
2 July 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol in the Respimat® Soft Mist™ Inhaler...
news
U.S. FDA grants Breakthrough Therapy Designation to Pradaxa® (dabigatran etexilate) specific investigational antidote
30 June 2014 | By Boehringer Ingelheim
The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to the investigational antidote idarucizumab...
news
New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation
23 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation...
news
Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials
17 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin...
news
Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism
6 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism...
news
Boehringer Ingelheim announces successful resolution of FDA warning letter
4 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that by a letter dated June 2, the United States Food and Drug Administration has informed the Company about the closure of the Warning Letter...
news
New data show Giotrif® (afatinib) provided more than one year additional survival for lung cancer patients with the most common type of EGFR mutation (del19) compared to chemotherapy
3 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced results of the pre-specified individual, as well as the exploratory combined, analyses of two Phase III trials (LUX-Lung 3 and LUX-Lung 6)...
news
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate) litigation
29 May 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the company has reached a comprehensive settlement of state and federal cases in the U.S. litigation regarding Pradaxa®...
news
Type 2 Diabetes: European Commission approves Jardiance® (empagliflozin)
23 May 2014 | By Boehringer Ingelheim
The European Commission has granted Marketing Authorisation for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor from Boehringer Ingelheim and Eli Lilly and Company...
